Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors

Inclusion Criteria

• •Woman with a history of breast cancer, stage 0, I, II, or III
• •At least 12 months from definitive surgical procedure (i.e. lumpectomy or mastectomy)
• •At least 3 months from completion of chemotherapy
• •Postmenopausal, defined as no menstrual cycle for 12 consecutive months, or surgical menopause
• •Have one or more stated symptoms of atrophic vaginitis, such as vaginal dryness, genital irritation/itching, genital pain, and/or dyspareunia
• •No current use of estrogen replacement therapy
• •If recent use of estrogen replacement therapy, off at least three months
• •No current use of estradiol-releasing vaginal ring or estradiol vaginal tablets; if recent use of these products, off at least 3 consecutive months
• •No evidence of disease (NED), any cancer other than breast cancer
• •No current use of oral omega 3 fatty acids or Vitamin E; if recent consistent use of these products, off at least six months; if sporadic use of these products, off at least 3 consecutive months
• •May be taking oral anti-estrogens or aromatase inhibitors, and/or biologic therapy
• •Must be willing to undergo venipuncture at 0, 3, and 6 months
• •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• •No history of a bleeding tendency
• •No history of uncontrolled hypertension, heart disease or stroke
• •Hemoglobin \> 10 g/dL
• •Hematocrit \> 30%
• •White blood count \> 3.5 K/uL
• •Platelet count \> 100,000/mm\^3
• •Fasting serum glucose \< 115 mg/dL
• •Total bilirubin \< 1.6 mg/dL
• •Transaminases alanine aminotransferase(ALT)and aspartate aminotransferase (AST)\< 1.5 x ULN (upper limit of normal)